Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic ChallengesMatteo Olivi, Marco Cerrano, Federica Di Biase et al.|Current Treatment Options in Oncology|2023Cited by 20
<scp>Validation of National Early Warning Score and Quick Sequential</scp> (<scp>sepsis‐related</scp>) <scp>Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy</scp>Chiara Frairia, Ernesta Audisio, Barbara Nicolino et al.|European Journal Of Haematology|2023Cited by 12
Validation of <scp>SIE</scp>/<scp>SIES</scp>/<scp>GITMO</scp> consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclaxVincenzo Apolito, Felicetto Ferrara, Giulia Arrigo et al.|British Journal of Haematology|2023Cited by 6
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experienceIrene Urbino, Marco Cerrano, Carolina Secreto et al.|Leukemia Research|2023Cited by 2
Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the LiteratureGiulia Arrigo, Chiara Frairia, Stefano D’Ardìa et al.|Medical Research Archives|2025Cited by 0